Law & Regulation
Webinar: Healing October 7th – Using MDMA for PTSD in Israel (Presented by MAPS Israel)
“Healing October 7th: Using MDMA for PTSD in Israel” is a live webinar event brought to you by Maps Israel, Neuly, and Psychedelic Invest. It will…
“Healing October 7th: Using MDMA for PTSD in Israel” is a live webinar event brought to you by Maps Israel, Neuly, and Psychedelic Invest. It will be held on Tuesday, January 30th at 11:00am ET.
During this conversation, moderator Dustin Robinson speaks with the CEO and Entrepreneur in Residence at MAPS Israel, Keren Tzarfaty, and Eyal Gura. The trio will talk about how MAPS Israel and how the healing powers of MDMA can play a role for many in Israel.
Be sure to RSVP to reserve your spot for this important online event.
Participants
Dustin Robinson
Dustin is a leader within the psychedelic ecosystem and has been ranked by Psychedelic Invest as the Top 100 Most Influential People in Psychedelics. As a licensed attorney and CPA with a law firm that exclusively works in the cannabis and psychedelic space and as the founder of a leading non-profit that is paving the way for psychedelic legalization, Dustin is an expert in understanding and capitalizing on opportunities within highly regulated industries. Dustin has been featured in top publications (i.e. Forbes) for his deep knowledge, experience, and advocacy in the psychedelic space; and his law firm has been listed by Psychedelic Invest as one of the Five Psychedelic Law Firms You Should Have on Your Radar.
Keren Tzarfaty
Keren Tzarfaty, Ph.D., MFT, is a co-founder of the Hakomi Institute of Israel and a Hakomi Trainer. She is also a trainer for MAPS (Multidisciplinary Association for Psychedelic Studies) in Israel
Some key aspects of her background and career include:
- Education: Keren holds an MA in Somatic Psychology and a Ph.D. in East-West Psychology, both from the California Institute of Integral Studies in San Francisco
- Clinical Investigator: She is a clinical investigator in the MDMA PTSD FDA-approved clinical trial, examining the impact of MDMA-assisted psychotherapy on severe PTSD patients
- Open Access Project: Keren serves as the clinical director of the Open Access project of MAPS and the Israeli Ministry of Health (MOH), which offers MDMA-assisted therapy for 50 participants in five governmental hospitals in Israel
- Academic Founder: She is one of the founders of the new MA program at Haifa University, titled “Integrative Psychotherapy: Body, Mind, Spirit”
- Specialization: Keren specializes in integrating mindfulness-based psychodynamic psychotherapy with somatic attachment psychotherapy
- Presentations: She has presented on the principles of somatic clinical approach and its integration into psychedelic psychotherapy
Eyal Gura
Mr. Gura is the Co-Founder and Chairman of Zebra Medical Vision, a deep learning medical imaging company that will enable scalable healthcare for the 2 billion people to join the middle class by 2025. Eyal is an Angel investor and previously venture capitalist with Pitango Venture Capital, the largest venture capital fund in the Middle East. Formerly, Co-Founder: PicScout (acquired by Getty Images); PicApp (acquired by Ybrant Digital); The Gifts Project (acquired by eBay). Adviser, WebTeb.com, the leading Arabic medical portal. Member, Advisory Board, Tmura.org. Member of the Board, Latet. Founding Member, Tovanotb.org. Eyal is a faculty member at IDC’s Zell entrepreneurship program and a graduate of the Wharton Business School of the University of Pennsylvania. In 2014 Eyal was named a Young Global Leader by the World Economic Forum.
Mr. Gura is currently the Entrepreneur in Residence at MAPS Israel and a venture investor.
RSVP To Reserve Your Spot
-
Psilocybin1 week ago
California advances bill for psychedelics centers
-
Psilocybin5 days ago
Passover Perspectives: Psychedelics, Moses, and the Burning Bush
-
Psychedelics1 week ago
Psychedelics Can Offer More Than Therapy On Its Own
-
Psychedelics5 days ago
Algernon NeuroScience and the Centre for Human Drug Research to Present DMT Phase 1 Stroke Clinical Data at the Interdisciplinary Conference on Psychedelic Research June 6 – 8th, 2024
-
Psychedelics5 days ago
Revive Therapeutics Announces Type C Meeting Request Granted by FDA for Clinical Study of Bucillamine to Treat Long COVID
-
Psychedelics5 days ago
atai Life Sciences Announces Dosing of First Patient in Part 2 of Beckley Psytech’s Phase 2a Study Exploring BPL-003 Adjunctive to SSRIs in Patients with Treatment Resistant Depression
-
Psychedelics5 days ago
Silo Pharma Announces Positive Results for Intranasal PTSD Treatment
-
Psychedelics5 days ago
Silo Pharma Announces Positive Results for Intranasal PTSD Treatment